Hepion Pharmaceuticals Stock Beneish M Score
| HEPA Stock | USD 2.11 0.02 0.94% |
Hepion | Beneish M Score |
At this time, it appears that Hepion Pharmaceuticals is an unlikely manipulator. The earnings manipulation may begin if Hepion Pharmaceuticals' top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by Hepion Pharmaceuticals executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of Hepion Pharmaceuticals' earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
-4.53
Beneish M Score - Unlikely Manipulator
Hepion Pharmaceuticals Beneish M-Score Indicator Trends
The cure to earnings manipulation is the transparency of financial reporting. It will typically remove the temptation of the top executives to inflate earnings (i.e., to promote the idea of 'winning at any cost'). Because a healthy internal audit department can enhance transparency, the board should promote the auditors' access to all the record-keeping systems across the enterprise. For example, if Hepion Pharmaceuticals' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back.
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | 27.5 M | 18.1 M |
|
| |||||
| Total Current Assets | 24 M | 17.5 M |
|
| |||||
| Non Current Assets Total | 576.2 K | 606.6 K |
|
| |||||
| Property Plant Equipment | 89.2 K | 93.9 K |
|
| |||||
| Depreciation And Amortization | 83.9 K | 69.7 K |
|
| |||||
| Selling General Administrative | 6.5 M | 9.6 M |
|
| |||||
| Total Current Liabilities | 3.8 M | 5.3 M |
|
| |||||
| Non Current Liabilities Total | 4 M | 5.5 M |
|
| |||||
| Short Term Debt | 110.1 K | 115.9 K |
|
| |||||
| Long Term Debt | 141.3 K | 158.9 K |
|
|
Hepion Pharmaceuticals Beneish M-Score Driver Matrix
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to detect the potential manipulation of earnings. Understanding the correlation between Hepion Pharmaceuticals' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Hepion Pharmaceuticals in a much-optimized way. Analyzing correlations between earnings drivers directly associated with dollar figures is the most effective way to find Hepion Pharmaceuticals' degree of accounting gimmicks and manipulations.
Click cells to compare fundamentals
About Hepion Pharmaceuticals Beneish M Score
M-Score is one of many grading techniques for value stocks. It was developed by Professor M. Daniel Beneish of the Kelley School of Business at Indiana University and published in 1999 under the paper titled The Detection of Earnings Manipulation. The Beneish score is a multi-factor model that utilizes financial identifiers to compile eight variables used to classify whether a company has manipulated its reported earnings. The variables are built from the officially filed financial statements to create a final score call 'M Score.' The score helps to identify companies that are likely to manipulate their profits if they show deteriorating gross margins, operating expenses, and leverage against growing revenue.
Depreciation And Amortization |
|
Hepion Pharmaceuticals Earnings Manipulation Drivers
Although earnings manipulation is typically not the result of intentional misconduct by the c-level executives, it is still a widespread practice by the senior management of public companies such as Hepion Pharmaceuticals. It is usually done by a series of misrepresentations of various accounting rules and operating activities across multiple financial cycles. The best way to spot the manipulation is to examine the historical financial statement to find inconsistencies in earning reports to find trends in assets or liabilities that are not sustainable in the future.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 20.6M | 48.6M | 103.6M | 60.2M | 18.1M | 27.5M | |
| Total Current Assets | 14.4M | 42.6M | 97.5M | 56.5M | 17.5M | 24.0M | |
| Non Current Assets Total | 6.2M | 6.0M | 6.1M | 3.7M | 606.6K | 576.2K | |
| Property Plant Equipment | 855.1K | 664.9K | 456.5K | 81.6K | 93.9K | 89.2K | |
| Depreciation And Amortization | 26.7K | 34.5K | 86.1K | 77.5K | 69.7K | 83.9K | |
| Selling General Administrative | 4.6M | 8.1M | 10.0M | 10.3M | 9.6M | 6.5M | |
| Total Current Liabilities | 1.6M | 4.7M | 8.2M | 7.9M | 5.3M | 3.8M | |
| Non Current Liabilities Total | 3.4M | 3.5M | 2.4M | 2.5M | 5.5M | 4.0M | |
| Net Debt | (13.1M) | (40.0M) | (91.0M) | (51.1M) | (14.6M) | (15.3M) | |
| Short Term Debt | 266.7K | 279.8K | 266.7K | 53.6K | 115.9K | 110.1K | |
| Operating Income | (7.8M) | (20.1M) | (30.4M) | (45.5M) | (48.4M) | (46.0M) | |
| Total Cash From Operating Activities | (7.6M) | (16.2M) | (31.2M) | (35.0M) | (40.9M) | (38.8M) | |
| Investments | (51.5K) | (85.8K) | (130.4K) | (14.1K) | (30.3K) | (31.8K) |
About Hepion Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Hepion Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Hepion Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Hepion Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Hepion Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Hepion Pharmaceuticals' short interest history, or implied volatility extrapolated from Hepion Pharmaceuticals options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Hepion Pharmaceuticals Piotroski F Score and Hepion Pharmaceuticals Altman Z Score analysis. For information on how to trade Hepion Stock refer to our How to Trade Hepion Stock guide.You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Complementary Tools for Hepion Stock analysis
When running Hepion Pharmaceuticals' price analysis, check to measure Hepion Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hepion Pharmaceuticals is operating at the current time. Most of Hepion Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Hepion Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hepion Pharmaceuticals' price. Additionally, you may evaluate how the addition of Hepion Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |
Is Hepion Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Hepion Pharmaceuticals. If investors know Hepion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Hepion Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (12.42) | Return On Assets (0.63) | Return On Equity (1.18) |
The market value of Hepion Pharmaceuticals is measured differently than its book value, which is the value of Hepion that is recorded on the company's balance sheet. Investors also form their own opinion of Hepion Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Hepion Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Hepion Pharmaceuticals' market value can be influenced by many factors that don't directly affect Hepion Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Hepion Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Hepion Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hepion Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.